Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0816 • ACR Convergence 2021
Analysis of Abatacept Treatment Retention and Efficacy According to Disease Duration and Treatment Line in a Real-World Setting
Rieke Alten¹, Xavier Mariette², Rene-Marc Flipo³, Roberto Caporali⁴, Maya Buch⁵, Yusuf Patel⁶, Raimon Sanmarti⁷, Sara Marsal⁸, Michael Nurmohamed⁹, Hedley Griffiths¹⁰, Peter Peichl¹¹, Bettina Bannert¹², Adrian Forster¹³, Melanie Chartier¹⁴, Yedid Elbez¹⁵, Christiane Rauch¹⁶, Vadim Khaychuk¹⁷ and Karissa Lozenski¹⁷, ¹Schlosspark-Klinik University, Berlin, Germany, ²Université Paris-Saclay, AP-HP, Hospital Bicêtre, Paris, France, ³Centre Hospitalier Universitaire de France, Lille, France, ⁴Policlinico S. Matteo University, Pavia, Italy, ⁵University of Leeds, Leeds, United Kingdom, ⁶Hull Royal Infirmary, Hull, United Kingdom, ⁷Hospital Clínic de Barcelona, Barcelona, Spain, ⁸Hospital Universitari Vall d’Hebron, Barcelona, Spain, ⁹ARC Amsterdam University Hospitals – VU University Medical & Reade, Amsterdam, Netherlands, ¹⁰Barwon Rheumatology Service, Geelong, Australia, ¹¹Evangelical Hospital, Vienna, Austria, ¹²Universitätsspital Basel, Basel, Switzerland, ¹³Schulthess Klinik, Zürich, Switzerland, ¹⁴Bristol Myers Squibb, Rueil-Malmaison, France, ¹⁵Deepscover, Puteaux, France, ¹⁶Bristol Myers Squibb, Munich, Germany, ¹⁷Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Longer disease duration and greater number of prior DMARDs have been associated with lower treatment efficacy in patients with RA.1 Abatacept is a biologic…
Abstract Number: 0833 • ACR Convergence 2021
Effectiveness of Upadacitinib in Patients with Rheumatoid Arthritis in German Real-World Practice: Interim Results from a Post-Marketing Observational Study
Torsten Witte¹, Uta Kiltz², Florian Haas³, Elke Riechers⁴, Ulrich Prothmann⁵, Daniela Adolf⁶, Carsten Holland⁷, Rouven Hecht⁸, Alexander Rössler⁷, Kirsten Famulla⁸, Konrad Götz⁸ and Klaus Krüger⁹, ¹Hannover Medical School, Hannover, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ³Internistisch-Rheumatologische Facharztpraxis, Tübingen, Germany, ⁴Department for Rheumatology and Immunology, Hannover Medical University, Hannover, ⁵Knappschaftsklinikum Saar, Püttlingen, Germany, ⁶StatConsult GmbH, Biometry and Data Management, Magdeburg, Germany, ⁷AbbVie Deutschland GmbH & Co. KG, Wiesbaden, ⁸AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁹Rheumatological Practice Center, Munich, Germany
Background/Purpose: Upadacitinib (UPA) is a Janus kinase inhibitor that has been shown to be effective and well tolerated in patients with rheumatoid arthritis (RA) in…
Abstract Number: 0967 • ACR Convergence 2021
Antigen-specific and Bystander Autoreactive T Cell Control in Peripheral Blood of ACPA+ Rheumatoid Arthritis Patients Administered Antigen-specific Tolerising Immunotherapy
Pascale Wehr¹, Ranjeny Thomas², Nishta Ramnoruth³, Swati Patel³, Jamie Rossjohn⁴ and Hugh Reid⁴, ¹University of Queensland Diamantina Institute, Brisbane, Australia, ²University of Queensland, Diamantina Institute, Brisbane, Australia, ³University Of Queensland, Brisbane, Australia, ⁴Monash University, Melbourne, Australia
Background/Purpose: The control of autoreactive T cells in an antigen-specific manner in autoimmune diseases is a major clinical research goal. Various regulatory immune signatures have…
Abstract Number: 1018 • ACR Convergence 2021
Joint-Draining Popliteal Lymphatic Vessels Exhibit Lymphatic Muscle Cell Dysfunction in TNF-Tg Mice with Inflammatory Arthritis
H. Mark Kenney¹, Yue Peng¹, Karen de Mesy Bentley¹, Chad Galloway¹, Homaira Rahimi², Lianping Xing³, Christopher Ritchlin⁴ and Edward Schwarz², ¹University of Rochester Medical Center, Rochester, NY, ²University of Rochester, Rochester, NY, ³University of Rochester Medical Center, Webster, NY, ⁴Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Lymphatic dysfunction is a factor in the onset and progression of rheumatoid arthritis (RA) (1). Our prior studies demonstrated reduced lymphatic clearance in the…
Abstract Number: 1158 • ACR Convergence 2021
Resistance of Patients with Rheumatoid Arthritis to Changing Therapy: A 15-year Follow-up
Kaleb Michaud¹, Sofia Pedro², Victoria Jasion³, Holly Budlong⁴, Jessica Suboticki⁵, Frederick Wolfe⁶ and Patricia Katz⁷, ¹University of Nebraska Medical Center, Omaha, NE, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³AbbVie, Overland Park, KS, ⁴AbbVie, Minneapolis, MN, ⁵AbbVie Inc., North Chicago, IL, ⁶National Data Bank for Rheumatic Diseases, Wichita, KS, ⁷University of California San Francisco, San Francisco, CA
Background/Purpose: Treatment options for rheumatoid arthritis (RA) have increased dramatically over the past 15 years. The objective of this study was to investigate whether willingness…
Abstract Number: 1209 • ACR Convergence 2021
Plasma Calprotectin as a Biomarker of Active Synovitis in Rheumatoid Arthritis: A Clinical and Ultrasound Study in Patients Treated with Il6 and JAK Inhibitors
Beatriz Frade-Sosa¹, Andrés Ponce², Roberto Gumucio³, José inciarte-Mundo⁴, María Torradeflot⁵, Virginia Ruiz-Esquide³, Rosa Morlà², Ana Belén Azuaga⁶, Núria Sapena², Marta Bassas², Julio Ramirez³, Juan D Cañete⁶, Jose A Gomez-Puerta¹ and Raimon Sanmarti¹, ¹Hospital Clínic de Barcelona, Barcelona, Spain, ²Rheumatology Department, Hospital Clínic, Barcelona, Spain, ³Rheumatology departmen. Hospital Clinic de Barcelona, Barcelona, Spain, ⁴Institut d'Investigacions Biomèdiques August Pi i Sunyer,( IDIBAPS), Barcelona, Spain, ⁵Immunology Department, Centre de Diagnòstic Biomèdic, Hospital Clínic de Barcelona, Universitat de Barcelona, IDIBAPS, Barcelona, Spain, ⁶Rheumatology Department, Hospital Clinic, Barcelona, Spain
Background/Purpose: IL6 inhibitors (IL6i) have a dramatic effect on acute phase reactants (AFR) such as C reactive protein (CRP) in rheumatoid arthritis (RA). However, CRP…
Abstract Number: 1225 • ACR Convergence 2021
Baseline Extracellular Matrix Biomarkers Predict Abatacept Treatment Response in MTX-Naive, ACPA+ Patients with Early RA
Paul Emery¹, Yoshiya Tanaka², Vivian Bykerk³, Clifton Bingham⁴, Tom WJ Huizinga⁵, Gustavo Citera⁶, Chun Wu⁷, Sarah Hu⁷, Peter Schafer⁷, Jinqi Liu⁷, Sean Connolly⁷, Robert Wong⁸ and Roy Fleischmann⁹, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and Leeds NIHR Biomedical Research Centre, Leeds, United Kingdom, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Division of Rheumatology, Hospital for Special Surgery, New York City, NY, ⁴Johns Hopkins University, Baltimore, MD, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁷Bristol Myers Squibb, Princeton, NJ, ⁸Bristol Myers Squibb, Basking Ridge, NJ, ⁹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Predictive biomarkers reflecting RA processes and treatment (tmt) efficacy are urgently needed to inform medical options. Markers of bone remodeling and extracellular matrix (ECM)…
Abstract Number: 1241 • ACR Convergence 2021
Comparison of the Effects of Upadacitinib Monotherapy with MTX on Protein Biomarkers in MTX-Naïve and MTX-Inadequate Responders in Patients with Active Rheumatoid Arthritis: Results from the SELECT-EARLY and SELECT‑MONOTHERAPY Phase 3 Studies
Thierry Sornasse¹, Heidi Camp², Fang Cai³, Justin Klaff² and Iain McInnes⁴, ¹AbbVie Inc, Redwood City, CA, ²AbbVie Inc., North Chicago, IL, ³AbbVie, Redwood City, CA, ⁴University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom
Background/Purpose: In MTX-naïve patients (SELECT-EARLY/M13-545 Phase 3 study) UPA 15 mg QD monotherapy (UPA Mono) demonstrated significant and clinically meaningful improvements in RA signs and…
Abstract Number: 1308 • ACR Convergence 2021
Higher Prevalence of Echocardiographic Abnormalities in Psoriatic Arthritis and Rheumatoid Arthritis Patients Compared to Controls
Alejandra Rodriguez-Romero, Jose Azpiri-Lopez, Dionicio Galarza-Delgado, Iris Colunga-Pedraza, Natalia Guajardo-Jauregui, Julieta Loya-Acosta, Alejandro Meza-Garza, Jesus Cardenas-de La Garza, Salvador Lugo-Perez, Catalina Andrade-Vazquez and Alan De Leon-Yañez, Hospital Universitario "Dr Jose E. Gonzalez", Monterrey, Mexico
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy associated with cardiovascular abnormalities. The echocardiography is a non-invasive tool useful in the detection of cardiac…
Abstract Number: 1532 • ACR Convergence 2021
Methotrexate Hampers Immunogenicity to BNT162b2 mRNA COVID-19 Vaccine in Immune-Mediated Inflammatory Disease
Rebecca Haberman¹, Ramin Herati¹, David Simon², marie Samanovic¹, Michael Tuen¹, Rebecca Blank³, Sergei Koralov¹, Raja Atreya⁴, Koray Tascilar⁵, Joseph Allen¹, Rochelle Castillo⁶, Amber Cornelius¹, Paula Rackoff³, Gary Solomon⁷, Samrachana Adhikari¹, Natalie Azar⁸, Pamela Rosenthal⁹, Peter Izmirly¹⁰, Jonathan Samuels¹¹, Brian Golden¹², Soumya Reddy⁹, Markus Neurath⁴, Steven B. Abramson¹⁰, Georg Schett¹³, Mark Mulligan¹ and Jose Scher¹⁰, ¹NYU Grossman School of Medicine, New York, NY, ²Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nrnberg, Erlangen, Germany, ³New York University, New York, NY, ⁴Deutsches Zentrum fur Immuntherapie, FAU Erlangen-Nuremberg and Universitatsklinikum Erlangen, Erlangen, Germany, ⁵Friedrich Alexander University of Erlangen Nuremberg, Universitaetsklinikum Erlangen Department of Medicine-3 Rheumatology and Immunology, Erlangen, Germany, ⁶NYU Langone Health, New York, NY, ⁷NYU Langone School of Medicine, Hartsdale, NY, ⁸NYU Langone, New York, NY, ⁹NYU School of Medicine, New York, NY, ¹⁰New York University School of Medicine, New York, NY, ¹¹NYU Langone, Rye Brook, NY, ¹²NYU Langone Medical Center - NYU Hospital for Joint Diseases, New York, NY, ¹³Universitätsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunology, Erlangen, Germany, Erlangen, Germany
Background/Purpose: Patients with immune mediated inflammatory disorders (IMIDs) have an inherently heightened susceptibility to infection and may be considered high risk for developing COVID-19. While…
Abstract Number: 1656 • ACR Convergence 2021
Women with Rheumatoid Arthritis Have More Multimorbidity Than Men in a Large Nationwide US Study
Hayley Dykhoff¹, Elena Myasoedova¹, Madeline Peterson¹, John Davis¹, Vanessa Kronzer¹, Caitrin Coffey¹, Tina Gunderson¹ and Cynthia Crowson², ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Eyota, MN
Background/Purpose: Patients with RA have an increased burden of multimorbidity. Although many comorbidities vary by sex, sex differences in multimorbidity among individuals with RA have…
Abstract Number: 1672 • ACR Convergence 2021
Many Better, Many Worse: Mean PROMIS-29 Scores Mask Significant Shifts During COVID-19 in RA
Susan Bartlett¹, Dana DiRenzo², Michelle Jones³ and Clifton Bingham², ¹McGill University, Montréal, QC, Canada, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins Medicine, Baltimore, MD
Background/Purpose: Rheumatic diseases (RD) are chronic conditions that require potent immunosuppressants to control systemic inflammation. Fears associated with increased vulnerability from being on immunosuppressants plus…
Abstract Number: 1688 • ACR Convergence 2021
Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 9.3 Years: An Updated Integrated Safety Analysis
Peter C Taylor¹, Tsutomu Takeuchi², Gerd Burmester³, Patrick DUREZ⁴, Josef Smolen⁵, Walter Deberdt⁶, Jinglin Zhong⁷, Jorge Ross Terres⁶, Natalia Bello⁶ and Kevin Winthrop⁸, ¹University of Oxford, Oxford, United Kingdom, ²Div. Rheumatology, Keio University, Tokyo, Japan, ³Charité University Medicine Berlin, Berlin, Germany, ⁴Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Brussels, Belgium, ⁵Medical University of Vienna, Vienna, Austria, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷IQVIA, Morrisville, NC, ⁸Oregon Health & Science University, Portland, OR
Background/Purpose: Baricitinib (bari) is an oral selective Janus kinase (JAK)1/JAK 2 inhibitor approved for the treatment of adult patients with moderately to severely active rheumatoid…
Abstract Number: 1704 • ACR Convergence 2021
Tofacitinib in Rheumatoid Arthritis: Is There a Correlation Between a Rapid Analgesic Effect and a Decrease in Activity After 3 and 6 Months?
Elena Pogozheva¹, Andrey Karateev¹, Evgeniy Nasonov¹, Alexander Lila¹, Vadim Mazurov², Rusanna Samigullina³, Diana Chakieva⁴, Anna Dadalova⁴, Anna Dyo⁴, Andrey Baranov⁵, Natalia Lapkina⁵, Ekaterina Kol’tsova⁶, Ivan Shchendrigin⁷, Tatyana Rasevich⁸, Antonina Davydova⁹, Irina Shafieva¹⁰, Inna Bashkova¹¹, Daria Bobrikova¹², Irina Kushnir¹³, Elena Kalinina¹⁴, Tatiana Sal’nikova¹⁵, Valentina Sorotskaya¹⁶, Irina Marusenko¹⁷, Olga Semagina¹⁸, Irina Vinogradova¹⁹, Diana Krechikova²⁰, Natalia Kiryukhina²¹, Irina Semizarova²², Dzhamilya Murtazalieva²³ and Marina Semchenkova²⁴, ¹V.A. Nasonova Reseach Institute of Rheumatology, Moscow, Russia, ²Mechnikov North-Western State Medical University, Saint Petersburg, Russia, ³Mechnikov North-Western State Medical University, St.Petersburg, Russia, ⁴Mechnikov North-Western State Medical University, St. Petersburg, Russia, ⁵Yaroslavl State Medical University, Yaroslavl, Russia, ⁶Scientific and Research Institute of Health Care Organization, Moscow, Russia, ⁷Stavropol Regional Clinical Hospital, Stavropol, Russia, ⁸Astrakhan Region Alexandro-Mariinsky Regional Clinical Hospital, Astrakhan, Russia, ⁹Regional Clinical Hospital №1 named. prof. S. V. Ochapovskogo, Krasnodar, Russia, ¹⁰Samara State Medical University of the Ministry of Health of the Russian Federation, Samara, Russia, ¹¹Advisory Polyclinic Chuvash State University named after I. N. Ulyanov, Cheboksary, Russia, ¹²Regional Clinical Hospital No. 1, Tyumen', Russia, ¹³Kemerovo regional clinical hospital, Kemerovo, Russia, ¹⁴Volgograd State Medical University, Volgograd, Russia, ¹⁵Regional Clinical Hospital, Tula, Russia, ¹⁶Tula State Medical University, Tula, Russia, ¹⁷Petrozavodsk State University, Petrozavodsk, Russia, ¹⁸Regional Clinical Hospital, Samara, Russia, ¹⁹Regional Clinical Hospital, Ulyanovsk, Russia, ²⁰Smolensk State Medical University, Smolensk, Russia, ²¹National Medical and Surgical Center named after N.I. Pirogov” of the Ministry of Healthcare of the Russian Federation, Moscow, Russia, ²²Regional Clinical Hospital, Krasnodar, Russia, ²³Moscow Clinical Scientific and Practical Centre named after Loginov A.S., Moscow, Russia, ²⁴Medical Clinical Centre, Smolensk, Russia
Background/Purpose: to investigate the correlation between the rapid analgesic effect of tofacitinib and a decrease in RA activity after 3 and 6 months.Methods: The study…
Abstract Number: 1916 • ACR Convergence 2021
Antibodies to Malondialdehyde-Acetaldehyde (MAA) Modified Proteins Predict Incident Rheumatoid Arthritis-Associated Interstitial Lung Disease
Bryant England¹, Geoffrey Thiele¹, Dana Ascherman², Michael Duryee¹, Carlos Hunter¹, Yangyuna Yang¹, Punyasha Roul¹, Harlan Sayles¹, Andreas Reimold³, Gail Kerr⁴, Joshua Baker⁵, Jill Poole¹ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pittsburgh, Pittsburgh, PA, ³University of Texas – Southwestern Medical Center/Dallas Veterans Affairs Medical Center (VAMC), Dallas, TX, ⁴Washington D.C., Veterans Affairs Medical Center (VAMC)/Georgetown and Howard Universities, Washington, DC, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: Because interstitial lung disease (ILD) causes substantial morbidity and mortality in rheumatoid arthritis (RA), there is a need for methods to facilitate early identification…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].